Miles Nunn
Director Técnico/Científico/I+D en AKARI THERAPEUTICS, PLC .
Fortuna: - $ al 31/05/2024
Perfil
Miles Nunn is currently the Chief Scientific Officer at Akari Therapeutics Plc since 2015.
Prior to this, he worked as a Director at Amplion Ltd., a Scientific Research Manager at Evolutec Group Plc, and as the Chief Scientific Officer at Volution Immuno Pharmaceuticals SA. Dr. Nunn holds a doctorate degree from the University of Oxford and an undergraduate degree from University College London.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AKARI THERAPEUTICS PLC
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
Cargos activos de Miles Nunn
| Empresas | Cargo | Inicio |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Director Técnico/Científico/I+D | 01/09/2015 |
Antiguos cargos conocidos de Miles Nunn.
| Empresas | Cargo | Fin |
|---|---|---|
Evolutec Group Plc
 Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Corporate Officer/Principal | - |
| Amplion Ltd. | Director/Miembro de la Junta | - |
Volution Immuno Pharmaceuticals SA
 Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Director Técnico/Científico/I+D | - |
Formación de Miles Nunn.
| University of Oxford | Doctorate Degree |
| University College London | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AKARI THERAPEUTICS, PLC | Health Technology |
| Empresas privadas | 3 |
|---|---|
Volution Immuno Pharmaceuticals SA
Volution Immuno Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Part of Akari Therapeutics Plc, Volution Immuno Pharmaceuticals SA is a Swiss company that develops anti-complement and anti-inflammatory molecules to treat orphan conditions in the autoimmune and inflammatory diseases sectors. The company is based in Geneva, Switzerland. The company was founded by Raymond Prudo-Chlebosz, who has been the CEO since incorporation. Volution Immuno Pharmaceuticals was acquired by Celsus Therapeutics Plc from RPC Pharma Ltd. on September 18, 2015 for $146.72 million. | Health Technology |
Evolutec Group Plc
Evolutec Group Plc BiotechnologyHealth Technology Evolutec Group Plc is an biopharmaceutical company, which discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. It was founded in1998 and headquartered in Oxford, United Kingdom. | Health Technology |
| Amplion Ltd. |
- Bolsa de valores
- Insiders
- Miles Nunn
